| Description | Ribocil-C is a highly selective bacterial riboflavin riboswitches inhibitor. |
| In vitro | Ribocil-C is a small-molecule synthetic mimic of FMN that binds the FMN riboswitch of multiple GN bacteria, including Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii, to inhibit ribB expression, RF synthesis, and consequently arrest bacterial growth. Ribocil-C specifically inhibits dual FMN riboswitches, separately controlling RF biosynthesis and uptake processes essential for Staphylococcus aureus growth and pathogenesis. Ribocil-C controls expression of de novo riboflavin biosynthesis in Escherichia coli [1][2]. |
| In vivo | Ribocil-C treatment groups (60 and 120 mg kg21 ribocil-C) show a dose-dependent reduction in the bacterial burden of 1.87 and 3.29 log10[CFU per g spleen] reduction respectively versus shamtreated mice. There is no mortality or gross effects of toxicity observed [2]. |
| molecular weight | 419.5 |
| Molecular formula | C21H21N7OS |
| CAS | 1825355-56-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 24.6 mg/mL (58.64 mM) |
| References | 1. Wang H, et al. Dual-Targeting Small-Molecule Inhibitors of the Staphylococcus aureus FMN Riboswitch DisruptRiboflavin Homeostasis in an Infectious Setting. Cell Chem Biol. 2017 May 18;24(5):576-588. 2. Howe JA, et al. Selective small-molecule inhibition of an RNA structural element. Nature. 2015 Oct 29;526(7575):672-7. |